Aardvark Therapeutics Stock (NASDAQ:AARD)
Previous Close
$12.60
52W Range
$4.88 - $19.58
50D Avg
$11.63
200D Avg
$10.82
Market Cap
$264.04M
Avg Vol (3M)
$62.37K
Beta
2.27
Div Yield
-
AARD Company Profile
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.